United States

JDRF is the leading global organization funding type 1 diabetes (T1D) research. The ongoing dedication to JDRF's mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications ensures that there will be a continuous stream of life-changing therapies moving from development through to the marketplace that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D and turn Type One into Type None. JDRF collaborates with a wide spectrum of partners at every stage of the drug and device delivery pipeline and is the only organization with the scientific resources, regulatory influence, and a strategic plan to deliver a world without T1D. JDRF’s influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia, and clinicians, because curing T1D is a global coordinated effort with JDRF leading the effort. Currently, JDRF is supporting $568 million in active T1D research projects worldwide. In 2016 alone, JDRF’s T1D research funding totaled more than $106 million. JDRF now has more than 570 research projects taking place throughout the globe. JDRF’s 2016 research funding included $78 million in U.S.-based projects and $28 million in international projects. Since its founding in 1970, JDRF’s cumulative research funding totals over $2 billion. JDRF is currently funding more than 50 clinical trials of potential T1D therapies. JDRF has worked with industry experts and established strategic roadmaps in Artificial Pancreas Systems, encapsulation of insulin producing cells, beta cell regeneration, antigen specific immunotherapy, prevention of T1D, prevention or treatment of diabetic complications of the kidney and eye, and other select areas. JDRF will be providing input and expertise to WPs 1, 5, 6, 7 and 8. More specifically, JDRF will be part of the Hypo-RESOLVE steering committee and thus contribute to the strategic governance of the project. JDRF will also be co-leading the Patient Advisory Committee (PAC), which ensures the project’s impact on patients by involving them in all aspects of the project, and advise every work package. The PAC will be involved in the design of the clinical trial, the development of the PRO, as well as communication with patient networks and the general public. Moreover, JDRF will provide regulatory expertise to facilitate the contact with the regulatory authorities both in Europe and in the US. JDRF is also providing an IMI-matched contribution of EUR 1 520 000 to Hypo-RESOLVE.

Dr Sanjoy Dutta, PhD

Assistant Vice President, Translational Development & International Partnerships. He strategically manages a portfolio of academic, biotech, and pharmaceutical initiatives and partnerships that evaluate a strong and promising pipeline of candidate drugs, devices, and related opportunities relevant for all ages and stages of T1D. He also leads all JDRF international research partnerships. Previously, he was associate director of translational medicine and clinical biomarkers at Bristol-Myers Squibb, overseeing the metabolic diseases therapeutic area. He obtained his doctorate from the department of biochemistry and molecular biology at the University of Southern California.

Dr Olivier Arnaud, PharmD

Senior Director, European Research. He is responsible for enhancing JDRF’s research efforts in Europe and working to identify new collaborations, partnerships and funding opportunities in academia and industry. Prior to joining JDRF, Dr Arnaud was responsible for licensing and research collaborations, as well as business development, leading alliance management activities, with oversight of business intelligence and development of operations. Dr. Arnaud completed his doctorate at Claude Bernard University in Lyon, France, with a specialized master’s degree in pharmacology and pharmacokinetics. He has also completed course work in business intelligence at the Institute of Higher National Defense Studies in Paris.

Dr Marlon Pragnell, PhD

Senior Scientist, Translational Development. He is responsible for developing and managing JDRF’s hypoglycemia prevention portfolio. Dr Pragnell’s responsibilities include the JDRF-funded CONCEPTT trial, an international effort that aims to improve maternal and fetal outcomes inT1D pregnancies through the use of CGM. Prior to joining JDRF, he was principal scientist at Genzyme in renal and metabolic diseases R&D. Dr Pragnell completed his doctorate from The University of Iowa and pursued postdoctoral training at Columbia University.

Dr Jeannette Soderberg, PhD

European Project Manager. She manages JDRFs European portfolio, which includes the INNODIA and BEAt-DKD IMI projects. Prior to joining JDRF, she was Project Manager at INCF, the International Neuroinformatics Coordinating Facility where she lead a team which developed a research infrastructure for Big Data analysis of clinical trial data. She served on the Management Committee of FP7 project CENTER-TBI. Dr Soderberg completed her doctorate from Stockholm University, Sweden and has also completed course work in Law at Stockholm University.

Ms Campbell Hutton, MSPH

Senior Director, Regulatory Affairs. She is responsible for JDRF’s interactions with regulatory agencies, including the U.S. Food and Drug Administration. In this capacity, she oversees the regulatory affairs team to develop and implement JDRF’s overall regulatory strategy for all of the JDRF priority areas of T1D research. This includes ensuring that academic sites gain the necessary regulatory approvals, providing regulatory assistance and oversight to JDRF partners, and interfacing with regulatory agencies about T1D research and development. Ms. Hutton joined JDRF in 2009 and prior to joining JDRF, Ms. Hutton was a Vice President, Strategic Consulting Group at Becker & Associates Consulting, a scientific consulting firm in Washington, D.C. Ms. Hutton holds a bachelor’s degree in biology from Washington and Lee University and a master’s degree in public health from the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill.

Mr Jesse Bushman

Senior Director of Health Policy. He has worked in the coverage and reimbursement policy field for 21 years, including positions with the Federal agency overseeing Medicare and Medicaid, the nation’s largest trade association for health insurers, a multi-national biopharmaceutical manufacturer and with two different provider organizations. He is lead in developing and implementing strategies to ensure availability of appropriate coverage for services and supplies used by Type 1 diabetes patients. He has consistently focused on advocacy with the Executive and Legislative branches regarding coverage and reimbursement under public and private health systems. Mr. Bushman earned a Master of Legislative Affairs from George Washington University.

Mr Benny Johnson

Regulatory Affairs Manager. He implements JDRF’s strategy to accelerate regulatory approval for priority devices, such as artificial pancreas technologies, encapsulated islets, continuous glucose monitors and other advanced diabetes technologies. He brings expertise with regulatory affairs in government, industry, and academic environments and has worked on over 50 FDA regulated pre-clinical studies. Mr Johnson earned a Bachelor of Science degree from Coastal Carolina University.